NI
NVCR icon

Numeric Investors’s NovoCure NVCR Stock Holding History

Numeric Investors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$7M Buy
346,517
+280,200
+423% +$5.4M 0.05% 352
2017
Q3 		$1.32M Buy
+66,317
New +$1.3M 0.01% 694

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Numeric Investors's NVCR Position: Q4 2017 in Review

Numeric Investors increased its NovoCure (NVCR) stake by 423% in Q4 2017, buying an estimated $5.4M and bringing the position to 346,517 shares worth $7M. The position accounts for 0.05% of the portfolio, ranked #352.

Numeric Investors first reported a position in NVCR in Q3 2017 and has held it in 2 quarters since. 128 funds tracked by Wall St. Rank hold NVCR as of Q4 2017.

  • Numeric Investors held 346,517 shares of NovoCure worth $7M as of Q4 2017.
  • Numeric Investors bought 280,200 NovoCure shares in Q4 2017, an estimated $5.4M.
  • NovoCure made up 0.05% of Numeric Investors's portfolio in Q4 2017, its #352 holding.
  • Numeric Investors first reported a position in NovoCure in Q3 2017 and has held it in 2 quarters since.
  • 128 funds tracked by Wall St. Rank held NovoCure as of Q4 2017.

Based on Numeric Investors's 13F filing for Q4 2017, filed 14 Feb 2018.